SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Robert W. Dubois · Study

Home/Author

Robert W. Dubois

8 works· latest 2018· 2 institutionscluster: provisional

h-index8

i108

Citations503

Works here8

00

06

14

15

16

18

Most cited in this library

Explaining Drug Spending Trends: Does Perception Match Reality?2000 · 120 citations
The GRACE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution2014 · 107 citations
Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis2006 · 84 citations
Cost–effectiveness thresholds in the USA: are they coming? Are they already here?2015 · 76 citations
Standards and guidelines for observational studies: quality is in the eye of the beholder2015 · 44 citations

Works

8 shown

Evaluation of person-level heterogeneity of treatment effects in published multiperson N-of-1 studies: systematic review and reanalysis

BMJ Open·2018·9 authors·review·Open access

18citations

PEER-REVIEWED JOURNAL EDITORS’ VIEWS ON REAL-WORLD EVIDENCE

International Journal of Technology Assessment in Health Care·2018·6 authors·Open access

13citations

No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals

Trials·2016·9 authors·Open access

41citations

Cost–effectiveness thresholds in the USA: are they coming? Are they already here?

Journal of Comparative Effectiveness Research·2015·1 author

76citations

Standards and guidelines for observational studies: quality is in the eye of the beholder

Journal of Clinical Epidemiology·2015·4 authors·Open access

44citations

The GRACE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution

Journal of Managed Care Pharmacy·2014·4 authors·Open access

107citations

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis

Journal of Managed Care Pharmacy·2006·3 authors·review·Open access

84citations

Explaining Drug Spending Trends: Does Perception Match Reality?

Health Affairs·2000·5 authors

120citations